Top 5 Trends in 2018 Myeloma News

The Five Trends in Myeloma News That Will Dominate 2018

IMF Chairman Dr. Brian G.M. Durie identifies five areas of myeloma news that will draw the most attention and energy in 2018. Dr. Durie applies a practiced eye to these topics, which range from molecular testing to new therapies for myeloma, and tells which are hot and which, perhaps, are not. Read Dr. Durie's blog. 

 

Tune Into the Best of ASH 2017 Teleconference

Did the excitement over CAR T-cell therapies news live up to expectations? What new myeloma drugs and treatment paradigms are now on the horizon? Dr. Brian G.M. Durie explains the most significant findings presented at the 59th American Society of Hematology annual conference for patients, caregivers, and other members of the myeloma community. Tune into this FREE IMF teleconference with a Q&A session on Thursday, January 11, 2018, at 4 p.m. PT / 7 p.m. ET.

 

FDA Expands the Use of Xgeva for Multiple Myeloma

The US Food and Drug Administration (FDA) has expanded the use of Amgen’s Xgeva® (denosumab) to include the prevention of skeletal-related events in patients with multiple myeloma. The expanded use is based on randomized phase III clinical trial data that illustrated lesser renal toxicities with denosumab. In this IMF video filmed at ASCO in 2017, Dr. Noopur S. Raje (Massachusetts General Hospital Cancer Center), the study’s principal investigator, discusses the impact of denosumab compared with zoledronic acid on renal function in the treatment of myeloma bone disease.

A Journey Into the Five Senses

Claudia Meyer, a world-renowned artist, will be hosting “Sensoria” - a solo art show - at the Castelli Art Space at 5440 W. Washington Blvd. in Los Angeles from February 3-11, 2018. A portion of all sales of her works from this event will benefit the International Myeloma Foundation. Claudia describes “Sensoria” as “a visual extrapolation of the five senses.” Get a glimpse into this imaginary world and learn more at Claudia Meyer’s website.

Taking the Work Out of Play

Have you ever wanted to organize a Member FUNdraiser, but you do not have one more inch to spare on your already full plate? The IMF is here to make the process stress-free for you. If you are already planning an event (a birthday party, a backyard barbecue, a bake sale, and so forth), the IMF will help you turn that event into a fundraiser. We will promote your event on our website so people can make an online donation on your behalf. No extra work for you — just take your already planned event to raise myeloma awareness and much-needed funding for our mutual cause. Call Suzanne Battaglia (800) 452-2873 ext. 227 or email sbattaglia@myeloma.org just to chat, and we can go from there. 

Should the cost of Revlimid (lenalidomide) be reduced?

In this week’s video, Dr. Brian G.M. Durie addresses why the cost of patented drugs, such as Revlimid, have not yet been reduced.

This weekly newsletter is supported from funds by donors like you. Donate to continue to make publications like this one possible.

We Thank Our Sponsors: Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology